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Background: A sensitive, high-throughput method for monitoring pre-mRNA splicing on a genomic scale is
needed to understand the spectrum of alternatively spliced mRNA in human cells.
Results: We adapted Molecular Inversion Probes (MIPs), a padlock-probe based technology, for the multiplexed
capture and quantitation of individual splice events in human tissues. Individual MIP capture probes can be
quantified using either DNA microarrays or high-throughput sequencing, which permits independent assessment
of each spliced junction. Using our methodology we successfully identified 100% of our positive controls and
showed that there is a strong correlation between the data from our alternative splicing MIP (asMIP) assay and
quantitative PCR.
Conclusion: The asMIP assay provides a sensitive, accurate and multiplexed means for measuring pre-mRNA
splicing. Fully optimized, we estimate that the assay could accommodate a throughput of greater than 20,000
splice junctions in a single reaction. This would represent a significant improvement over existing technologies.
Background
During alternative splicing a single gene transcript is
processed into several discrete mRNA isoforms, each of
which contains different exonic sequences and can code
for distinct proteins. These genetically related gene pro-
ducts can have diverse, sometimes antagonistic cellular
functions (see BCL2L1 as an example [1]). Mis-splicing
has been implicated in numerous human diseases [2-4]
and therefore knowing the alternative splicing landscape
of human tissue provides a starting point for evaluating
splicing events as diagnostic markers for disease.
We wanted to develop an improved high-throughput
method to precisely map the splicing events that dictate the
spatial and temporal transcriptional content of an organism.
Some low-throughput technologies that have worked for
small numbers of genes include: reverse transcription poly-
merase chain reaction (RT-PCR), northern blots, real-time
or quantitative PCR (qPCR) [5], the TaqMan assay [6], and
Sanger sequencing. These technologies are effective for
individual genes, but do not scale to whole-transcriptome
analyses. DNA microarrays have been used to detect alter-
native splicing on a genomic scale, but data analysis has
proven challenging due to their small dynamic range (less
than 100-fold) [7] and high degree of cross-hybridization;
related exon-exon junctions can have greater than 50%
sequence similarity, making unambiguous assignment of
each probe difficult [8,9]. To overcome these challenges
researchers will typically assay different classes of tissues
(e.g. brain versus non-brain) instead of individual tissues
making single sample analysis difficult or impractical [9-11].
De novo high-throughput sequencing (HTS) is by far the
most promising new technology for detecting novel splice
sites [12,13]. The drawbacks of using whole transcriptome
HTS to characterize alternative splicing are currently
expense and limited dynamic range; the dynamic range is
decreased for splicing studies because of the predominance
of uninformative sequence, which overwhelms the small
amount of alternatively spliced exon junction data obtain-
able. High-throughput sequencing would be much more
effective if the sequences of interest could be captured prior
to sequencing. Molecular Inversion Probes (MIPs) provide
this exact utility; they quantitatively capture only the nucleic
acid sequences of interest, which decreases cost and
increases the dynamic range of individual sequencing runs.
* Correspondence: kjuneau@stanford.edu
† Contributed equally
1Stanford Genome Technology Center, Department of Biochemistry, Stanford
University School of Medicine, Palo Alto, CA USA
Full list of author information is available at the end of the article
Lin et al. BMC Genomics 2010, 11:712
http://www.biomedcentral.com/1471-2164/11/712
© 2010 Lin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.MIPs are long, single stranded oligonucleotides that
contain two interrogation sequences at their termini, one
or two sequence tags for parallel readout with either
microarrays or high-throughput sequencing, and two
amplification primers that flank the sequence tags and
are common to all MIPs (Figure 1). The MIP assay is per-
formed in three steps: hybridization, circularization and
amplification. During the MIP assay, probes hybridize to
either side of a specific nucleic acid target sequence and
bound MIPs are selected by circularizing the probes via
ligation and amplified using common primers. MIPs can
then be quantified using microarrays or HTS. The MIP
technology was pioneered in our laboratory [14,15] and
has been used to measure gene copy number in colorec-
tal carcinoma [16] and quantify allele frequency in 56 dif-
ferent human cell lines [17]. We have now applied this
technology to the analysis of alternative splicing.
Another sequencing capture strategy, which has been
used to study alternative splicing, is cDNA-mediated
annealing, selection, extension and ligation (DASL) [18].
DASL is very similar to the MIP alternative splicing
strategy we developed, but with an important difference;
interrogation sequences, barcodes and amplification
sites are contained on two separate DASL probes
whereas MIPs include all these components on a single
probe. Thus, significantly higher concentrations of
DASL probes are necessary for corresponding probes to
find each other. Subsequently, cross-hybridization is an
issue and multiplexing is limited to approximately 1500
probe-pairs [18]. In comparison, MIPs are effective at
orders of magnitude lower concentration because the
hybridization of the first interrogation sequence acceler-
ates the hybridization of the second in a unimolecular
reaction and cross-hybridization between MIPs is negli-
gible. Thus, MIPs have been successfully multiplexed in
sets of nearly 40,000 [19] and it is predicted that
100,000plex reactions are feasible [15].
This paper describes the development of a MIP-based
assay for the high-throughput detection of alternative
splicing events. The MIPs can accurately and quantita-
tively measure alternative splicing events for a number
of genes in a variety of tissues. We looked at 208 exon
junctions in 17 genes across five tissues, a total of 1040
splice events (208 × 5 = 1040). We showed that indivi-
dual alternative splicing MIP (asMIP) measurements
correlate well with direct qPCR measurements, as well
as provide a concordance index (c) of 0.96 when com-
pared with a set of known splicing controls. Moreover,
we correctly identified tissue-specific splicing for 100%
of the alternatively spliced control exons we assayed. In
summary, we successfully developed a novel, high-
throughput asMIP assay that can efficiently detect and
quantify alternatively spliced exon junctions in a variety
of tissues.
TTTTTT
AAAAAA
TTTTTT
0
2
-2
Sample preparation
TTTTTT
asMIP hybridization
asMIP circularization
asMIP amplification and quantitation
4 1 2 3 4 1 2 3
A
B
Probe design
Figure 1 A schematic of the asMIP methodology. (A) The asMIP
design. Unreacted probes terminate with 3’- and 5’-interrogation
sequences (no. 1) abutted by two DraI cleavage sites (no. 2). Each
probe contains two unique sequence tags (no. 3) and two common
primer binding sites (no. 4). (B) The asMIP assay. Step 1, sample
preparation: immobilized cDNA was reverse transcribed (arrow) from
polyadenylated RNA (curved lines followed by AAAAAA) using
oligo-dT primers (TTTTT), which were covalently attached to
magnetic beads (gray circles). Following cDNA synthesis, RNA is
digested and washed away. Step 2, asMIP hybridization: unreacted
asMIP probes (flattened nicked circles) terminate with 3’- and 5’-
interrogation sequences (gray and colored lines), which are
homologous to the exon sequences that flank splice junctions on
the cDNA. Probes quantitatively anneal to the appropriate exon-
exon junction (colored probes). Probes that do not hybridize (gray
probes) are washed away. Step 3, asMIP circularization: bound
asMIPs are ligated into circles (small arrows). Step 4, asMIP
amplification and quantitation: only the successfully ligated probes
(contiguous circles) can be exponentially amplified using the
common PCR primers (thin black lines). Each probe contains two
unique sequence tags, which are amplified by PCR for multiplexed
detection via array hybridization or high-throughput sequencing
(bar graph).
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Developing and testing an alternative splicing MIP assay
We set out to develop a MIP-based assay that could mea-
sure exon-exon junctions quantitatively and identify alter-
native splicing events. To obtain this level of sensitivity we
customized the design of the MIP probes and optimized a
rigorous four-step protocol: sample preparation, asMIP
hybridization, circularization, and amplification (Figure 1).
There are four main differences between our single-
stranded, DNA-based, alternative splicing MIPs (asMIPs)
and the original single-nucleotide polymorphism (SNP)
MIPs: 1) we included two sequence tags, 2) there is no
gap between the probe termini when accurately annealed,
3) we did not include any deoxyuridine nucleotides
between the amplification primers [14] and 4) we synthe-
sized the target cDNA with primers that were covalently
attached to magnetic beads; this allowed for extensive
washing between enzymatic reactions, which likely
improved quantitation by decreasing the background.
Seventeen genes, including 208 total exon-exon junc-
tions, were selected to test the new asMIP assay. We
identified 11 candidate genes that splice differentially in
neural tissue [10], three genes that express distinct iso-
forms in smooth and skeletal muscle (TPM1, TPM2,
and TPM3) [20] and three housekeeping genes (ACTB,
GAPDH, TUBA1B), which served as loading controls
(Table 1). In total, our set of known positive alternative
splicing controls contained 14 genes, 25 exon-skipping
events and 58 exon-exon junctions.
Minimal probe concentrations are required for the MIP
assay
Our goal was to develop a high-throughput alternative
splicing assay. Since the level of multiplexing possible for a
ligation-based splicing assay is inversely correlated with
probe concentration, we needed to show that the assay
was reproducible with very small amounts of asMIPs. In
our standard assay we used 10 femtomoles (fmol) of each
probe in a 30 μl assay (333 pM). We compared the array
intensities from the standard 10 fmol reaction against
reactions with probe concentrations of 1 fmol and 0.1
fmol. We obtained R
2 values of 0.98 and 0.94, respectively,
demonstrating that we could decrease probe concentration
10- to 100-fold without diminishing data quality (Addi-
tional Files 1A and 1B). Since our pilot asMIP experiments
were approximately 200plex, this suggests that without
optimization, performing a 20,000plex quantitative asMIP
assay would be straightforward.
Probe effects are addressed using either a biological
reference or statistically modeled baseline
We built two analysis methods that extract and score
alternative splicing information from asMIP and qPCR
exon-junction data. For both methods we show that
splice scores are significantly smaller for constitutive
junctions than alternatively spliced junctions, which pro-
vides a straightforward approach for identifying alterna-
tively spliced junctions.
The two asMIP analysis methods we developed both
account for the sequence-based probe effects that fre-
quently confound inter-probe comparisons. One method
uses a biological reference (R-score), which is particu-
larly useful if there is a well-defined or biologically
meaningful reference sample that can be used as a base-
line to make informative comparisons across different
experiments. This reference-based score does require
prior knowledge of which junctions are constitutive and
can be negatively impacted by poor annotation or a lim-
ited number of constitutive sites. Our second analysis
method is not dependent upon the accurate identifica-
tion of gene-specific constitutive junctions and it does
not require a biological reference. Instead, we used the
data across all the tested tissues to build an additive,
model-based score (M-score) for each gene. Different
sample sets will result in differently modeled baselines,
which in turn will affect M-score interpretation in the
same way that different biological reference samples
would affect R-scores.
Table 1 asMIP targets
Gene tissue specificity con
1 alt
2 total
CAMK2D* neural 8 (4) 5 (5) 13 (9)
CLTB* neural 3 (3) 3 (3) 6 (6)
EHBP1* neural 8 (3) 4 (4) 12 (7)
ERC1* neural 8 (4) 10 (10) 18 (14)
FEZ2* neural 2 (2) 9 (9) 11 (11)
MARK4 neural 8 3 11
MINK1 neural 11 10 21
MLLT4 neural 9 10 19
MYH10 neural 15 8 23
MYO6 neural 10 6 16
TPD52 neural 3 6 9
TPM1 muscle 5 7 12
TPM2 muscle 5 6 11
TPM3 muscle 4 6 10
ACTB control 5 0 5
GAPDH control 8 0 8
TUBA1B control 3 0 3
totals: 115 93 208
Numbers in parentheses correspond to total junctions analyzed by qPCR.
1 The number of predicted constitutive exon junctions targeted by asMIPs
indentified from RefSeq [21].
2 The number of potentially alternatively spliced exon junctions targeted
identified from RefSeq [21], of which 58 were confirmed in the literature to be
alternatively spliced in the tissues we studied [10,20].
* Genes that were assayed with both asMIPs and qPCR.
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should score near zero while alternatively spliced junc-
tions should have scores that differ substantially, either
positively or negatively, from zero. To test our metho-
dology, we identified a collection of 99 negative control
junctions; these junctions are predicted to be constitu-
tively spliced given that they are present in every mRNA
isoform curated by the Reference Sequence Database
(RefSeq) [21]. We then compared the constitutive junc-
tions to a set of 58 positive control junctions; these
junctions are known to be alternatively spliced in the
tissues we studied [10,20]. We found that when the
absolute values of the R-a n dM-scores were plotted for
the two sets of control junctions, they deviated signifi-
cantly from each other (p-value < 0.001) regardless of
which technology was used (qPCR, asMIP-sequencing
and asMIP-arrays). As expected, the constitutively
spliced negative controls clustered tightly near zero; in
comparison, the junctions known to be alternatively
spliced provided significantly higher absolute values
(Additional File 2).
Using receiver operating characteristic (ROC) curves
we further evaluated the R- and M-score methodologies.
Using the positive controls described above as our set of
true-positives we calculated the areas under the curves
(AUCs, equivalent to concordance index c) for all three
technologies; positive controls were assigned a value of
1, negative controls were 0. The AUCs for the asMIP
technology ranged between 0.89 and 0.96; AUCs for
qPCR were 1.0 (Figure 2A and Table 2). We concluded
that both R-a n dM-scoring strategies easily distin-
guished known alternative splicing events from constitu-
tive ones.
The asMIP results are correlated with direct qPCR analysis
With our analyses in place, we compared 235 qPCR-
derived splice scores with asMIP splice scores and
found that the data sets were highly correlated. Addi-
tionally, we observed that the sequenced asMIP data
combined with the M-score analysis provided the best
results.
We found a positive correlation between the splice
scores for asMIPs and qPCR (Table 2 and Additional
File 3). Given how extensively the two methods, qPCR
and asMIPs, differ we did not expect, nor did we see, a
perfectly linear agreement, but the correlation we did
see supported our conclusion that asMIPs quantitatively
measure alternative splicing events when either analysis
method (R-score or M-score) is used.
Using receiver operating characteristic (ROC) curves
we further evaluated the performance of the asMIPs
compared to qPCR (Figure 2B). To carry out this analy-
sis we first transformed all quantitative qPCR splicing
scores into ternary splicing calls by assigning positive
and negative cutoffs to the data; splice scores above or
below the positive and negative cutoffs for each data set
would receive splice calls of +1 and -1 and be labeled as
alternatively spliced, while scores between the cutoffs
would have a splice call of zero and would be labeled
constitutive. For qPCR, we used the mean plus and
minus three standard deviations to obtain cutoffs for
R-a n dM-scores (+/-5.7 and +/-2.7 respectively). To
plot an ROC curve that combined both positive and
negative splicing data, it was necessary to convert tern-
ary splice scores (1, 0, and -1) into binary scores (non-
zero versus zero); true positives necessarily had the
same sign (plus or minus) in both data sets. There were
some instances where the qPCR data had the opposite
sign as the asMIP data and thus, the ROC curves did
not reach the upper right-hand corner of the graph (Fig-
ure 2B). Separate ROC curves for positive and negative
splicing data can be found in Additional File 4.
We chose to use the asMIP M-score sequencing data
for the majority of our downstream biological analyses
because, compared to the other three methods (R-score
array, R-score sequencing, and M-score array), it pro-
vided the largest area under the curve (0.76). Splicing
calls were specified from this data using a cutoff of
+/-1.3, which provided a good balance between sensitiv-
ity and specificity (0.68 and 0.72 respectively).
100% of the tissue-specific exon-skipping controls were
identified using asMIPs
Using the asMIP data, we were able to confirm the tis-
sue-specific alternative splicing of all 25 skipped exon
controls with two or more asMIPs.
In this study we included three well-characterized tropo-
myosin genes that are frequently used as models for alter-
native splicing (TPM1, 2 and 3) [20]. These genes are
known to have strong muscle-specific splicing patterns.
Indeed, when we looked directly at the raw, un-normalized
sequencing counts for asMIPs interrogating exon junc-
tions in TMP1 and 2 (Figures 3C &3D) and compared the
results for skeletal muscle (black) with smooth stomach
muscle (blue) it was apparent that smooth muscle exon
junctions predominated in the smooth muscle tissue,
while skeletal exon junctions predominated in the skeletal
muscle. It is also evident from the raw data that the consti-
tutive junctions, which might be expected to have similar
counts, instead display large variations due to inherent
sequence-based probe effects (Figures 3C &3D). Both the
R-a n dM-scores account for these probe effects. Conse-
quently, alternative splicing is better visualized in the
M-score plots (Figures 3E &3F) where the constitutive
junctions (the first five junctions plotted) score near zero,
while the alternative junctions (last 6 or 7 junctions
plotted) clearly score above and below the established cut-
off (+/-1.3, gray dashed lines). Notably, we found that the
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fic splicing of all 19 exon junctions associated with the 11
skipped exons in all three tropomyosin genes tested.
We next looked at our neural-specific splicing controls
by comparing our asMIP M-score from sequence data
against new or previously published gel electrophoresis
data [10]. The splicing of exon-6 in FEZ2 is shown in
detail as an example (Figure 4A). To evaluate the neural-
specific splicing controls, we compared two tissues,
stomach and frontal lobe, then tallied the number of
alternatively spliced exon junctions that were observed.
These two tissues were chosen because they best repre-
sented the splicing differences seen for non-neural versus
neural-specific tissues when assayed by gel electrophor-
esis [10]. In one case, ERC1, the expression levels of the
gene in stomach and skeletal muscle were too low to
obtain asMIP measurements, thus, placenta data were
used. For the neural-specific genes we identified 36/39
alternatively spliced junctions and were able to confirm
all 13 exon-skipping events in 11 genes. The three missed
junctions bridged the skipped exons from three genes:
FEZ2, MLLT4,a n dMYO6. Interestingly, in all three
genes where this occurred the short isoform was
expressed well in all tissues while the long isoform was
only expressed appreciably in the two neural tissues [10].
Thus, the failure to detect alternative splicing of the
three bridging junctions may not indicate a technological
error, but instead reflect the physiological isoform
expression differences between these tissues.
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Figure 2 The asMIP data correctly characterize splicing controls and correlate with qPCR measurements. Receiver Operating
Characteristic (ROC) curves comparing asMIP data with (A) junctions known from the literature to be alternatively spliced and (B) qPCR data.
Data from asMIPs quantified using sequencing is black, asMIP data from arrays is blue; R-score data are dashed lines; M-score data are solid lines.
(A) An analysis of 157 tissue specific splicing events: 58 positive alternative splicing controls [10,20] and 99 predicted constitutive negative
controls [21]. For this plot, only relevant pairs of tissues, known to show alternative splicing for the genes assayed, were included in the
calculation of R- and M-scores; skeletal and stomach data were used for tropomyosin genes, stomach and frontal lobe for brain specific genes,
placenta and frontal lobe for ERC1. Absolute values of these scores were used. To generate the standard for comparison, positive spicing
controls were assigned a value of 1, negative constitutive controls were 0. (B) An analysis of the 235 splicing events that were studied using
both qPCR and asMIPs. For this plot we transformed ternary splice scores (1, 0, and -1) into binary scores (non-zero versus zero). Because there
were cases where the qPCR and asMIP scores had the opposite sign, the ROC curves do not reach the upper right-hand corner of the graph.
Individual ROC curves for positive or negative splice calls are located in Additional File 4. The solid black circle marks the point on the M-score
sequencing line that corresponds to the +/-1.3 cutoff, which was used to identify alternative splicing.
Table 2 Evaluation of asMIPs using splicing controls and
qPCR data
Statistic R-Array R-Seq M-Array M-Seq
AUC-controls
1 0.90 0.96 0.89 0.96
AUC-qPCR
2 0.65 0.65 0.65 0.76
CorrqPCR-controls
3 (r) 0.84 0.86 0.63 0.82
CorrqPCR-total
2 (r) 0.44 0.64 0.29 0.59
The table includes results from both the R- and M-score analyses (R- and M-),
as well as data from asMIPs quantified with either arrays (Array) or
sequencing (Seq). AUC and Pearson correlation (Corr, r) values are reported.
1 asMIP data was compared to tissue specific, splicing controls from the
literature: 58 tissue specific, alternatively spliced junctions [10,20] and 99
predicted constitutive junctions [21,34].
2 asMIP data was compared to the complete set of qPCR data, 235 tissue
specific splice events were analyzed.
3 asMIP data from the set of splicing controls was compared to qPCR data
from the same set of controls [10,20,21,34], 34 tissue specific splice events
were analyzed.
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Page 5 of 14The asMIPs are capable of identifying splice events in
individual tissues, as well as previously uncharacterized
alternative splicing events
Using asMIPs quantified by sequencing and analyzed
using the additive model (M-score) we detected 249 tis-
sue-specific alternative-splicing events (out of 1040
total). The majority of which (79%) occurred in our set
of potentially alternatively spliced junctions; these junc-
tions were expected to show some degree of alternative
splicing since they mapped to unique isoforms in the
RefSeq database [21]. We used qPCR and gel electro-
phoresis to test approximately 30% of the identified
junctions. We show that our method is capable of iden-
tifying splicing events within individual tissues, as well
as events that displayed complex splicing patterns across
multiple tissues. To illustrate this we discuss three spe-
cific examples in detail: TPD52, CAMK2D, and MINK1.
Tumor protein D52 (TPD52) is a small vesicle-
trafficking protein that has been shown to be over
expressed in a variety of human cancers [22]. TPD52 is
known to have three isoforms [21]. Isoform-2 (NCBI
Accession NM_001025253.1), which lacks exon-2, has
been found to be the predominant isoform in brain tis-
sue [10,23]. Using our asMIP data we were able to verify
the expression of brain-specific isoform-2 and extend
the analysis further to show that isoform-1 (NCBI
Accession NM_001025252.1), which lacks exons 1, 6,
and 7, is highly expressed in stomach tissue (Figure 4B).
These splicing results for TPD52 demonstrate that
asMIPs can identify tissue-specific splicing within a
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Figure 3 Tissue-specific alternative splicing of TPM1 and TPM2 are confirmed using asMIPs. Tissue-specific isoforms and splice-score data
are color-coded; skeletal muscle is black, stomach is blue, and reference sample data is yellow. (A & B) Schematic representations of two muscle
specific isoforms. Exons are represented by numbered boxes. Thin lines depict introns. (C & D) Graphs of the raw sequence counts for asMIPs
interrogating the exon junctions specified (e.g. 4-5, 5-6 et cetera). Signal variation for constitutive junctions is due predominantly to sequence-
based probe effects. (E & F) Graphs of the M-scores for each junction in which probe effects, gene expression differences and experimental
variance have all been accounted for. The first five junctions listed for the gene are constitutively spliced and the remaining junctions are
alternatively spliced. In (E & F) both the sequencing data (squares) and array data (diamonds) are presented for comparison. The gray dashed
lines show the cutoff (+/-1.3) used to make splicing calls. The tissue-specific splicing of these control genes are clear; known constitutive
junctions map near zero, alternatively spliced junctions all map above or below the cutoffs.
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Page 6 of 14single tissue; clustering of similar tissues prior to analy-
s i s ,a si sc o m m o n l yd o n ef o ra r r a yd a t a[ 9 - 1 1 ]i s
unnecessary.
Calcium/calmodulin-dependent protein kinase II delta
(CAMK2D) is a serine/threonine protein kinase and the
regulated splicing of exons 14, 15 and 16 helps direct
postnatal heart remodeling [24]. There are six CAMK2D
isoforms reported by RefSeq [21] and a seventh that was
identified by Clark et al. 2007, which we also validated as
being neural specific. The neural-specific isoform lacks
exon 14, but contains exons 15 and 16. Our asMIP stu-
dies on CAMK2D also demonstrated that isoform-3
(NCBI Accession NM_0012211.3), which contains exon
22, was preferentially expressed in skeletal muscle (Figure
4C); again implicating the involvement of CAMK2D in
muscle function. Interestingly, this junction was initially
mis-labeled in our dataset as being constitutive, but the
asMIP data along with the M-score analysis was able to
correctly identify it as being alternatively spliced (Figure
4 C ) .T h i sr e s u l te x e m p l i f i e sh o was i n g l ea s M I Pi nas i n -
gle tissue can provide valuable splicing information even
when the junction is thought to be constitutive.
Misshapen-like kinase 1 (MINK1) encodes a serine/
threonine kinase that is involved in cytoskeleton reorga-
nization, cell adhesion and cell motility [25]. MINK1 is
alternatively spliced into four different isoforms [21]. In
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Figure 4 Splice scores compare well with RT-PCR data. Tissue-specific alternative splicing data are shown for four genes: FEZ2 (A), TPD52 (B),
CAMK2D (C) and MINK1 (D). In each panel schematic representations of the analyzed splice junctions are shown on top. Exons are depicted as
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quantified asMIPs (diamonds) and qPCR (triangles). The M-score data are plotted for five different tissues: placenta (PLA), skeletal muscle (SKM),
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“5-6” corresponds to data for the junction between exons five and six). Gray dashed lines show the M-score cutoffs for qPCR (+/-2.7) and asMIP
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comparison with the graph. The exons contained within each PCR gel band are specified to the right of each gel.
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Page 7 of 14neural tissue, we verified that exon 21 was preferentially
included in the mRNA [10] (not shown) and showed
that exon 18 was excluded (Figure 4D), along with a
shortened version of exon 16 (not shown). Only one of
the four isoforms contains these specific exonic
sequences, suggesting that a single isoform predomi-
nates in neural tissue, isoform-2 (NCBI NM_170663.3).
We were also able to identify the single isoform (iso-
form-4 (NCBI Accession NM_001024937.2)) that is
most highly expressed in stomach tissue by matching
asMIP data with known isoforms; in stomach, exon 21
is preferentially excluded while exon 18 and the short
form of exon 16 are included. The MINK1 gene illus-
trates how asMIPs can identify relevant splicing events
within complex tissue-specific patterns of alternative
splicing.
Our detailed analysis revealed that the asMIPs not
only confirmed the alternative splicing of our controls,
b u ta l s oe x t e n d e dw h a tw a sk n o w nr e g a r d i n gt h et i s s u e
specificity of individual isoforms.
High-throughput sequencing appears to outperform
arrays for asMIP quantitation
We quantified our pools of reacted asMIPs either with
DNA microarrays or HTS. Our results consistently
showed that HTS outperformed arrays for quantifying
asMIPs. For example, AUC and correlation values were
significantly better (p-values < 0.05) for asMIPs quanti-
fied by HTS compared to array quantitation in three out
of four analyses (Figure 2, Additional File 3 and Table
2). In addition, more of our positive splicing controls
were identified when asMIPs were sequenced (100%)
than when hybridized to arrays (96%). These data all
suggest that the asMIP assay is more accurate when
probes are quantified with high-throughput sequencing
although arrays do perform adequately and could pro-
v i d eam o r ec o s te f f e c t i v em e a n so fq u a n t i f y i n gM I P s
for some research projects.
Discussion
In summary, we have developed a novel MIP-based
alternative splicing assay that is sensitive, specific, and
can be highly multiplexed. We compared our asMIP
and qPCR methodologies and found that the correlation
between asMIP and qPCR is good; for sequenced asMIP
M-scores the Pearson correlation coefficient was 0.59 or
0.82 depending on the data set (Table 2) and the AUC
was 0.76 (Figure 2B). Furthermore, when we looked at a
set of splicing controls from the literature, sequenced
asMIPs provided an AUC value of 0.96 (Figure 2A) and
successfully identified 100% of the known, alternatively
spliced exons along with 93% of their related junctions
(for examples see Figure 3 and 4A). Additionally, several
previously uncharacterized, tissue-specific splice events
were revealed (Figures 4B-D). We have also shown that
asMIP probes can be diluted to sub-femtomolar quanti-
ties (Additional File 1B). We conclude that the asMIP
assay is capable of accurate, multiplexed quantitation of
alternative splicing in human tissues; our data suggests
that 20,000plex reactions will be feasible in the near
future.
The advantage of using a sequence capture strategy to
analyze alternative splicing in samples that could, in the-
ory, be quantified directly using high-throughput
sequencing is that you can dramatically increase the
dynamic range of sequencing runs by increasing the
amount of usable data. For example, if one looked at
20,000 exon junctions captured by asMIPs with 20-mil-
lion short sequence reads, the dynamic range would be
three orders of magnitude (10
3). If one directly
sequenced the sample with 20-million short reads
mapped to the genome, only about 4% of those reads
would likely overlap any exon junction (800,000 reads)
[13]. If there are approximately 22,000 genes in the
human genome with an average of 9-10 junctions (total-
ing ~200,000 junctions) [26] the dynamic range drops to
4 (800,000/200,000 = 4), less than one order of magni-
tude for direct sequencing.
One major advantage of asMIPs over other parallel
sequence capture technologies such as DASL [18] is high
level of multiplexing that is possible with unimolecular
probes. Highly multiplexed reactions require small
a m o u n t so fp r o b ea n dw es h o w e dt h a to n l ym i n u t e
amounts of each asMIP are necessary for quantitative
alternative splicing measurements; asMIP reactions car-
ried out with 100 attomole (amol) of each probe were
tightly correlated (R
2 = 0.94) (Additional File 1B). SNP
MIPs have already been successfully used in ~40,000plex
reactions [19] and 100,000plex reactions have been pro-
posed [15]. The actual limit of multiplexing for MIPs has
not been determined; it could, in practice, be significantly
greater than 100,000plex.
Exon arrays also provide a high level of multiplexing,
but the large variation in probe hybridization [8-11] and
the smaller dynamic range [7] often confounds data ana-
lysis and impedes the identification of individual tissue
specific splicing changes. The asMIP assay does not
appear to suffer from the same limitations and conse-
quently, can accurately identify independent tissue-
specific splicing changes, like those seen for TPD52 and
CAMK2D (Figures 4B &4C), whereas exon arrays strug-
gle with the same task [9-11].
The asMIPs are well suited for quantifying known
alternative splice events accurately in a single tube using
a minimum of sample, but there are projects for which
the technology is not ideal; large-scale analyses on a
small number of samples might not be cost-effective
and novel splice sites can not be identified using this
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Page 8 of 14method. Certainly, economies of scale would offset the
initial financial outlay for large libraries of oligonucleo-
tide probes and thus, asMIP collections would be a valu-
able resource, easily shared among laboratories.
However, researchers conducting global splicing studies
on only a few samples will likely find HTS more attrac-
tive than asMIPs, particularly when a large dynamic
range is not essential. Similarly, researchers desiring to
map isoforms or identify a collection of potential cancer
biomarkers de novo would likely use high-throughput
sequencing. But once those biomarkers have been iden-
tified then asMIPs are perfectly poised to accurately and
cost-effectively characterize those splicing biomarkers in
patient samples. Indeed, by barcoding each asMIP reac-
tion prior to quantitation one could assay 1000 splice
junctions in 20 samples using a single HTS reaction,
producing a >1000-fold dynamic range. In this case,
employing asMIPs would be less expensive and provide
a larger dynamic range than carrying out 20 separate
HTS reactions.
Conclusions
We conclude that our asMIP technology can effectively
quantify alternative splicing in human tissues and is well
adapted for in-depth splicing studies on several hundred
to tens-of-thousands of biologically important splice
junctions in a variety of organisms.
Methods
MIP synthesis and design
Molecular Inversion Probes (MIPs) are single stranded
DNA oligonucleotides with lengths ranging between 130
and 150 bases, synthesized in-house, using standard
methods. Probes were used without purification at a
cost of approximately $0.08 per base. For large scale stu-
dies it may be advisable to synthesize the oligos on
DNA microarrays prior to bulk amplification via PCR
[27] and subsequent transformation of the amplicons to
single-stranded probes [28]. The architecture of the
alternative splicing MIPs (asMIPs) differ only slightly
from the original SNP MIPs (Figure 1A) [14]; the
asMIPs contain an additional sequence tag (two tags
total). The arrangement of specific sequences along the
asMIP probe, in order from five-prime to three-prime,
are as follows: 1) 5’-exon-junction interrogation
sequence, 2) DraI cleavage site, 3) first sequence tag, 4)
reverse PCR primer binding site GTGGTCTATG
TCGTCGTTCG, 5) forward PCR primer binding site
CGCTTTAGGT GCAGACACAA, 6) DraI cleavage site,
7) second sequence tag, 8) 3’-exon-junction interroga-
tion sequence. Interrogation sequences were targeted to
cDNA sequences that flank exon-exon splice junctions;
the lengths of the interrogation sequences were adjusted
so that each Tm (melting temperature) would be near
60°C [29]. Sequence tags were 20-bases long and com-
plementary to sequences contained on the TAG4 DNA
microarray [30].
Synthesis of immobilized cDNA
Human total RNA was obtained for five individual tissues
and one tissue mixture from Clontech: placenta (catalog
no. 636527), skeletal muscle (catalog no. 636534), stomach
(catalog no. 636578), cerebellum (catalog no. 636535),
frontal lobe (catalog no. 636563), and Human Universal
Reference Total RNA (REF) (catalog no. 636538).
Immobilized cDNA was synthesized on Dynabeads Oligo
(dT)25 (Invitrogen catalog no. 61002) according to the
manual. Briefly, polyA+ mRNA was purified from 1 μgo f
total RNA (Clontech) that was mixed with 5 μl of Dyna-
beads in 20 μl binding buffer (20 mM Tris-HCl pH 8.0, 2
m ME D T A ,1ML i C l ) .T h eb e a d sw e r ew a s h e dt h r e et i m e s
at room temperature in 50 μl of wash buffer (1 mM Tris-
HCl pH8.0, 1 mM EDTA, 0.15 M LiCl ). Reverse transcrip-
tion (RT) was carried out in 20 μl of RT mix (4 μl5 ×R T
buffer (Invitrogen, catalog no. 18080-044), 1 μl0 . 1MD T T ,
1 μl SuperScript III (Invitrogen, catalog no. 18080-044),
1 μl 10 mM dNTPs, 13 ul water); RT reactions were incu-
bated and rotated in UVP-HB-500 Mini Hybridization
Oven (UVP, Upland, CA, USA) at 50°C for 30 minutes and
then at 55°C for an additional 30 minutes. RNA was
removed by incubating the completed cDNA synthesis
reaction with 5U RNase H. Immobilized cDNA was
washed and resuspended in 10 μl washing buffer.
MIP selection: target hybridization and probe
circularization
The asMIP reaction is carried out in three parts: probe
hybridization, circularization, and signal amplification/
quantitation. A multiplexed pool of 208 asMIP oligos,
each at a concentration of 0.5 nM, was used for the
assay.
Target hybridization
Each asMIP reaction required 20 μl of the asMIP pool;
the pool was denatured in 1× Ampligase buffer (Epicen-
ter, catalog no. A3202k) at 95°C for 5 minutes, then
chilled on ice before being added to the prepared immo-
bilized cDNA (10 μl). Hybridization of the MIPs to the
cDNA took place in three steps: the mixture was incu-
bated at 70°C for 10 minutes, slowly cooled at ~1 degree
per minute to a final temperature of 58°C, then held at
58°C for another two hours. After incubation, the
annealing reaction was washed three times with Dyna-
bead wash buffer, twice at 58°C and once at room
temperature.
Probe circularization
The wash buffer was removed from the beads and 10 μl
of ligation mix (1 μl Ampligase, 1 μl 10× ligation buffer
and 8 μl water) was added; the ligation reaction was
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Page 9 of 14incubated at 58°C for 30 minutes. Following ligation, the
beads were washed three times with Dynabead wash
buffer: twice at 58°C and once at room temperature.
The wash buffer was removed and beads were resus-
pended in 40 μl of TE (10 mM Tris, 1 mM EDTA, pH
8.0). Circularized MIPs were dissociated from the cDNA
by holding the sample at 95°C for 5 minutes and chilled
on ice. The ligated MIPs were further purified and fully
eluted from the immobilized cDNA by digesting all lin-
ear DNA with exonucleases; 4 μl of exonuclease mix
(3.5 μl 10× Exonuclease Buffer, 0.5 μl Exo I (NEB cata-
log no. M0293S. 1 μl Exo III (NEB catalog no.
M0206S)) was added to the MIP reaction and samples
were incubated at 37°C for 45 minutes. The exonu-
cleases were inactivated by heating samples to 94°C for
20 minutes.
MIP amplification and labeling
Microarray sample preparation
The specific process used for amplifying circularized
asMIPs was tailored to the method of quantitation; for
arrays, MIPs were amplified with biotinylated PCR primers
before being hybridized to microarrays. Specifically, 1 μlo f
eluted asMIPs were added to a 50 μl PCR reaction con-
taining 5’-biotinylated P1 and P2 (P1: bio-CGAAC-
GACGA CATAGACCAC, P2: bio-CGCTT TAGGT
GCAGACACAA) primers at 0.6 μM concentration and
1× Platinum PCR SuperMix (Invitrogen, catalog no.
11306-016). PCR reactions were carried out using the fol-
lowing three-step thermal profile: denaturation at 94°C for
15 seconds, annealing at 60°C for 1 minute and extension
at 72°C for 5 s. The resulting PCR products were treated
with 20 u of DraI (NEB catalog no. R0129S) incubated at
37°C for 1 hour; DraI digestion was used to separate the
two labeled sequence tags, as well as remove the now
extraneous interrogation sequences, which could con-
found hybridization.
High-throughput sequencing asMIP sample preparation
Unique primers were used to amplify asMIPs quantified
using Illumina HTS; in all other respects the PCR reac-
tion conditions were identical to those specified for
microarray sample preparation. The primers used for
HTS contained: 1) the adaptor sequences used for clus-
ter generation, as specified by Illumina (see underlined
sequence below, 2) a two-nucleotide barcode (NN) that
was sample specific so that seven tissue-specific samples
could be quantified in a single sequencing channel and
3) the common primers contained within the asMIPs.
Explicitly the sequences of the forward and reverse pri-
mers, respectively, are as follows: for sequencing Tag 1,
AATGATACGG CGACCACCGA GATCTACACT
CTTTCCCTAC ACGACGCTCT TCCGATCTNN
CGACGACATA GACCAC and CAAGCAGAAG ACG
GCATACG AGCTCTTCCG ATCTCGCTTT AGGTG
C A G A CA C A A ;f o rs e q u e n c i n gT a g2AATGATACGG
CGACCACCGA GATCTACACTC TTTCC CTACA
CGACGCTCTT CCGATCTNNT TAGGTGCAGA
CACAA and CAAGCAGAAG ACGGCATACG
AGCTCTTCCG ATCTCGAACG ACGACATAGA
CCAC.
Microarray hybridization and quantitation
Genflex Tag 16K Array v2 chips (Affymetrix, catalog no.
511331) were pre-hybridized with 90 ul 1× hybridization
buffer (100 mM MES pH 6.6, 1 M NaCl, 20 mM EDTA,
0.01% Tween 20) for 15 minutes at room temperature.
After removal of the hybridization buffer, 0.2, 2.0 or
20 μl of DraI-cut, biotinylated asMIP sample was hybri-
dized to the array in a sample buffer that contained: 1×
hybridization buffer, 1× Denhardt’s( S i g m a - A l d r i c h ,c a t -
alog no. 30915), 1 pmol/μl anti-sense oligonucleotides
that were reverse complementary to forward and reverse
PCR primers, and 0.6 fmol/μl B213 control oligonucleo-
tide (bio-5’-CTGAACGGTAGCATCTTGAC-3’). The
linear dynamic range of the arrays is limited to two
orders of magnitude (100-fold) (Additional File 1C). For
this assay we needed to increase the linear dynamic
range of the data we collected so we hybridized three
volumes of biotinylated asMIP sample (0.2, 2.0 or 20 μl)
for each tissue type. This effectively increased the
dynamic range by 100-fold to approximately four orders
of magnitude. Arrays were washed and stained using a
GeneChip fluidics station 450 (Affymetrix, Santa Clara,
CA, USA) and scanned on a GeneChip scanner 7G
(Affymetrix, Santa Clara, CA, USA). Fluorescent data
were extracted using the GeneChip operating software
version 1.4 provided by Affymetrix.
High-throughput sequencing
Purified asMIP ligation products were amplified with
modified sequencing primers (described above). Ampli-
fication products were analyzed by gel electrophoresis
and the products from six tissue samples (placenta,
skeletal muscle, stomach, cerebellum, frontal lobe, and
the universal reference) were combined for parallel
sequencing. Molecular Probes PicoGreen DNA quanti-
tation kit (Molecular Probes, catalog, no. P-7589) was
used to precisely quantify the combined MIP products,
1 . 4n go fw h i c hw a su s e df o rs e q u e n c i n go nt h eI l l u -
mina Genome Analyzer (Illumina, San Diego, CA,
USA). We obtained 1.9 million reads from a single
lane of sequencing, which could be uniquely mapped
to the asMIP sequence tags. Only perfect sequence
matches were counted. The average coverage per tag
was 984X, with a maximum coverage of 38,000X; 75%
of all tags had more than 10 reads.
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quantitative-PCR (qPCR)
Two sets of primers were designed to interrogate each
exon-exon junction for qPCR quantitation; the primer sets
were designed such that one primer would hybridize across
the exon-exon junction with exactly five 3’-nucleotides
on the downstream side and the remaining 17+ nucleotides
on the up-stream side of the junction. We designed two
sets of primers for each junction; in one set the forward pri-
mer crossed the junction while the reverse primer was posi-
tioned <100 nucleotides downstream, in the other the
reverse primer crossed the junction and the forward primer
was <100 nucleotides upstream. The primers were designed
to have melting temperatures above 60°C [29].
The cDNA samples were reverse transcribed from the
same tissue-specific RNA used for the asMIP studies.
We used the protocol and reagents provided in the
SuperScript III Kit (Invitrogen, catalog no. 18080-044)
to reverse transcribe 1 μg of tissue-specific total RNA
(Clontech) in a 20 μl reaction containing 2.5 μM oligo
dT(20) primer.
Quantitative PCR reactions contained 0.2 μlo ft h e
above reverse transcription reaction and 10 μl of a reac-
tion mix prepared by pre-mixing 0.5 μMo fb o t hf o r -
ward and reverse primers with 1× SYBR Green PCR
Master Mix (Applied Biosystems, catalog no. 4309155).
Using a 7900 HT real time PCR system (Applied Biosys-
tems, Foster City, CA, USA) reactions were denatured
for 10 minutes at 94°C, followed by a two-step amplifi-
cation cycle: 94°C for 5 seconds then 60°C for 60 sec-
onds. Data were collected during the 60°C incubation.
We used the SDS RQ Manager 1.2 software from
Applied Biosystems to calculate a cycle threshold(Ct) for
each primer set in six cDNA samples: five tissue-specific
samples plus the Universal Reference mixture of tissues
(REF). The relative tissue-specific expression level is
defined as the difference in Ct values between two samples
(ΔCt); the ΔCt for each primer set was calculated by sub-
tracting the tissue-specific Ct value from the Universal
Reference (e.g. for primer set 1, ΔCt
1
liver =C t
1
REF -C t
1
liver). As described above, each junction was interrogated by
two sets of primers; if both primer sets worked, ΔCt data
were averaged for the samples. If one of the two sets failed
then the data were not combined and only the informative
primer set was used in downstream calculations. In total,
ΔCt data were collected for 47 exon-exon junctions in five
individual human tissues, which provided data for 235
splice events (47 × 5 = 235). The qPCR data were used to
test the alternative splicing identification methodology we
developed for the asMIP array and sequencing data.
Data processing used to identify alternative splicing events
The five main steps/analyses we used to test the asMIP
assay and identify alternative splice are as follows:
1. Subtract background fluorescence signal
(microarrays).
2. Identify and select data in dynamic range
(microarrays).
3. Calculate normalized splice scores using a reference
sample (R-score).
4. Calculate normalized splice scores using a statistical
model (M-score).
5. Identify cutoffs for assigning alternative splicing
events.
Background subtraction
The background was defined as the average signal inten-
sity across 20 unused features common to all TAG4
microarrays. Each raw data point was normalized by
subtracting the background. After the background sub-
traction, we calculated the standard deviation (SD) of
the 20 unused spots, data points having values at or
below 1.96 times the SD weree x c l u d e df r o mf u r t h e r
analysis. This method of background subtraction was
used for analyzing the microarray data, but was not
necessary for analyzing the qPCR or HTS data.
Identify and select data in dynamic range
To increase the dynamic range of the microarrays by 100-
fold we hybridized each tissue-specific asMIP sample to
three arrays at three sample dilutions that differed by ten-
fold (0.2, 2.0 or 20 μl of sample per array). The lower end
of the dynamic range for each chip was equal to the back-
ground plus 1.96 × SD (described above). The upper end
of the dynamic range was based upon informed observa-
tion and set at 3500 units. To identify the sample dilution
(0.2, 2 or 20 μl) that provided the best array data for all the
data points within a specific gene, we identified the sample
dilutions having the most data points within the dynamic
range. We did this simple analysis for each gene, in every
tissue, at all three sample dilutions (0.2, 2 and 2.0 μl).
Calculate R-scores
We calculated a tissue-specific R-score (reference based
score) for each junction in each tissue. To address tech-
nical probe effects for asMIPs resulting from sequence-
related hybridization differences and enzymatic reaction
biases we calculated
dii =−  0 (1)
where θ denotes log base 2 of array intensities or Illu-
mina digital counts, i denotes tissue sample and 0
denotes reference sample. Our reference sample is a
commercially produced mixture of tissues from Clon-
tech (Human Universal Reference Total RNA, catalog
no. 636538). The log transformation was chosen for the
sequencing data because we had numerous counts for
each tag (median = 94) and the distribution of the data
was right-skewed; we assumed and later verified that the
probe effects were additive at the log scale.
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lines of gene expression, for each candidate junction j in
gene g, we calculated
fdd jkig jkig ckig ,, , ,, , ,, , =− (2)
where c denotes tissue-specific constitutive junction
data (constitutive annotation based on BLAST [31]
alignment of common isoforms), and k denotes tag
measures (1 or 2) for each junction. In order to normal-
ize between genes, we averaged the f-measure over the
two tags for each junction and then calculated our R-
score as
Rf s jig jig g ,, ,, / = (3)
where g denotes genes, sg denotes the standard devia-
tion of f calculated for all constitutive asMIPs for that
gene. This procedure is performed using R (http://www.
r-project.org/) function rlm for robust estimation. Nor-
malizing for gene specific variation using sg was impor-
tant when making inter-gene splicing rankings, which
was necessary to plot the ROC curves in Figure 2 and
Additional File 4. Calculating the R-scores for qPCR was
identical to the calculations made for asMIP data once
it was taken into consideration that output for qPCR
(cycle threshold (Ct)) is already log2 transformed. For
example, the qPCR log2 ratio of sample to reference was
calculated by simply subtracting the Ct for the reference
from the Ct of the sample and so forth.
Calculate M-scores
To build an analysis method that requires no prior
knowledge of which junctions are alternatively spliced
and to identify an alternative method to evaluate our
technology using the pilot data, we applied an additive
model to produce M-scores for each junction in each
tissue. In brief, we have
 jkig jkg ig jkig pt ,, , ,, , ,, , =+ + (4)
where θ represents log base 2 of the raw signals, j
denotes junctions, i denotes tissues, g denotes genes, k
denotes tag measures (1 or 2) for each junction, p
denotes technical effects, t denotes baseline gene expres-
sion level, and ε denotes random errors with mean 0
and variance s
2. Our model is similar to the FIRMA
model [32], previously developed for detecting differen-
tial alternative splicing using exon arrays. With this
modeling strategy, we hope to robustly estimate and
address in our current data both the technical effects, by
averaging over all tissues for each junction (i.e. replace
θ0 in equation (1) with ˆ ,, p jkg) and the baseline of gene
expression, by averaging over all junctions for each tis-
sue and each gene (i.e. replace dcig ,, in equation (2)
with ˆ
, tig). The estimation of these parameters were per-
formed using median polish [33], which fitted an addi-
tive model by alternatively removing the row (-junction)
and column (-tissue) medians until the proportional
reduction of the sum of absolute residuals is negligible
[33]. The above described procedure provided us with
f jkig jkig ,, ,
*
,, , =  (5)
where f*i sa n a l o g o u st of in equation (2). Our final
M-score is calculated as
Mf s jig jig g ,, ,,
** / = (6)
where s*g is the MAD of f* in all junctions and tissues
in gene g. For more details please see our step-by-step
example for calculating the M-scores for the CLTB gene
(Additional File 5).
Following our analysis, we tested our assumption that
t h ep r o b ee f f e c t sw e r ea d d i t i v eb yv e r i f y i n gt h el i n e a r i t y
and normality of our additive model with sequencing
data. We found no significant deviations from these
assumptions when there were at least four reads per tag
(85% of all data).
We used only the known splice junction controls to
generate Figure 2A, Additional File 2 and rows 1 and 3
in Table 2. We calculated M-scores and R-scores using
just the pairs of tissues known to show alternative spli-
cing for the genes assayed; skeletal and stomach data
were used for tropomyosin genes, stomach and frontal
lobe for brain specific genes, placenta and frontal lobe
for ERC1. To plot the ROC curve in Figure 2A we used
the absolute value of the splice score differences from
each pair of tissues. These differences are also splice
scores with the baseline expression shifted to one of the
tissues in each pair. These tissue-restricted M-a n d
R-scores were compared with the splicing controls. Con-
stitutive splicing controls were assigned a value of 0;
alternatively spliced controls were assigned 1.
Cutoff Identification
After calculating the R- and M-scores for all three sets of
data (qPCR, arrayed asMIPs, and sequenced asMIPs) we
identified cutoffs to categorize splicing events as alterna-
tively or constitutively spliced in our data set. Firstly, we
defined stringent cutoffs for the qPCR data in order to
compile a list of true positives. Any scores that are signifi-
cantly higher or lower than the boundary for the constitu-
tive junctions may point to candidate alternatively spliced
junctions. We chose a cutoff for the qPCR score that was
equal to the mean (-0.13 R-score and -0.05 M-score)
minus three standard deviations (5.55 R-score and 2.64
M-score) from the mean. The calculated cutoffs for R-
and M-score qPCR data were +/-5.7 and +/-2.7 respec-
tively; we assumed symmetry in the score for positive and
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Page 12 of 14negative changes. We used this cutoff to define a set of
true positives for alternative splicing events, which we
used to assess the asMIP results. The cutoff for the asMIP
data was 1.3, which provided a good balance between sen-
sitivity and specificity (0.68 and 0.72 respectively); to facili-
tate the comparison between array and sequencing
quantitation we assigned the same cutoff for both asMIP
readouts (arrays and HTS).
Additional material
Additional file 1: This figure shows the reproducibility of the asMIP
assay using decreasing amounts of probe library (Figures A & B),
and presents evidence that the linear dynamic range of the arrays
used to quantify asMIPs is approximately 100-fold (Figure C).
Additional file 2: Data presented in this figure demonstrate that
splice scores for alternatively spliced junctions are much larger
than for constitutive junctions.
Additional file 3: The plots in this figure show the correlation
between splice scores derived from asMIP assays compared to
qPCR.
Additional file 4: This figure shows two Receiver Operating
Characteristic (ROC) plots comparing qPCR splicing calls against
asMIP splicing calls made at various cutoffs for either the positive
(Figure A) or negative (Figure B) qPCR splicing calls.
Additional file 5: A detailed, step-by-step example calculation for
M-score for one gene.
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MIP: Molecular Inversion Probe; asMIP: alternative splicing Molecular
Inversion Probe; HTS: high-throughput sequencing; RT-PCR: reverse
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